NeoGenomics to Report Fourth Quarter and Full Year 2024 Financial Results on February 18, 2025
FORT MYERS, Fla.--(BUSINESS WIRE)--Jan 29, 2025--
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced that it will report its fourth quarter and full year 2024 financial results prior to the open of the U.S. financial markets on Tuesday, February 18, 2025. Company management will host a webcast and conference call at 8:30 a.m. ET to discuss financial results and recent highlights.
The live webcast may be accessed by visiting the Investor Relations section of our website at ir.neogenomics.com or by clicking here . The webcast will be archived and available for replay shortly after the conclusion of the call.
To access the live call via telephone, dial (888) 506-0062 (domestic) or (973) 528-0011 (international) at least five minutes prior to the call. The participant access code is 167039.
About NeoGenomics, Inc.
NeoGenomics, Inc. specializes in cancer genetics testing and information services, providing one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The Company's Pharma Services Division serves pharmaceutical clients in clinical trials and drug development.
Headquartered in Fort Myers, FL, NeoGenomics operates CAP accredited and CLIA certified laboratories for full-service sample processing in Fort Myers, Florida; Aliso Viejo and San Diego, California; Research Triangle Park, North Carolina; and Houston, Texas; and a CAP accredited full-service, sample-processing laboratory in Cambridge, United Kingdom. NeoGenomics also has several, small, non-processing laboratory locations across the United States for providing analysis services. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States, and pharmaceutical firms in Europe and Asia.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250129573716/en/
CONTACT: Investor Contact
Kendra Sweeney
[email protected] Contact
Andrea Sampson
[email protected] KEYWORD: FLORIDA UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: RESEARCH GENERAL HEALTH MACHINE TOOLS, METALWORKING & METALLURGY PHARMACEUTICAL ONCOLOGY HOSPITALS GENETICS CLINICAL TRIALS SCIENCE BIOTECHNOLOGY HEALTH OTHER SCIENCE MANUFACTURING
SOURCE: NeoGenomics, Inc.
Copyright Business Wire 2025. PUB: 01/29/2025 08:05 AM/DISC: 01/29/2025 08:05 AM
http://www.businesswire.com/news/home/20250129573716/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 minutes ago
- Yahoo
Mesoblast (ASX:MSB) Gains 15% In One Week With US FDA Orphan-Drug Approval
Mesoblast experienced a 15% increase in its share price over the past week, largely driven by a significant orphan-drug approval by the U.S. FDA for Ryoncil. This approval, granting seven years of exclusivity for a vital treatment, likely bolstered investor confidence given the strengthened competitive positioning of Mesoblast. While broader market trends saw the S&P 500 and Nasdaq reach new highs amid positive investor sentiment on U.S.-China trade discussions, Mesoblast's specific gains were more tied to its unique developments, as they provided a substantial boost, counterbalancing broader market movements. You should learn about the 1 warning sign we've spotted with Mesoblast. Explore 22 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research. Over the past three years, Mesoblast's total shareholder return, including share price changes and dividends, reached 181.00%. Despite recent gains driven by the U.S. FDA's orphan-drug approval for Ryoncil, the company's one-year performance outpaced the broader Australian Biotechs industry, which returned 12.3% less in the same timeframe. This highlights significant investor confidence and a positive reception to recent strategic advancements. While Mesoblast's share price has experienced impressive growth, it still trades at approximately 88% below consensus analyst price targets. The approval of Ryoncil positions the company competitively, potentially boosting future revenue, as evidenced by the expanded insurance coverage to 104 million U.S. lives. However, Mesoblast remains unprofitable, with A$47.93 million in net losses reported in its recent earnings. Analysts forecast substantial revenue growth at 56.7% annually, but profit forecasts show continued challenges for the next three years. The stock's recent appreciation reflects increased optimism, although the gap between the current share price and targeted fair value suggests room for further market adjustments. Our comprehensive valuation report raises the possibility that Mesoblast is priced lower than what may be justified by its financials. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ASX:MSB. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
24 minutes ago
- Business Insider
SailPoint, Inc. (SAIL) Receives a Rating Update from a Top Analyst
TD Cowen analyst Shaul Eyal maintained a Buy rating on SailPoint, Inc. (SAIL – Research Report) today. The company's shares closed today at $22.53. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Eyal is a top 25 analyst with an average return of 26.7% and a 69.56% success rate. Eyal covers the Technology sector, focusing on stocks such as Cloudflare, SailPoint, Inc., and Check Point. In addition to TD Cowen, SailPoint, Inc. also received a Buy from Barclays's Saket Kalia in a report issued on June 3. However, today, Mizuho Securities reiterated a Hold rating on SailPoint, Inc. (NASDAQ: SAIL). SAIL market cap is currently $10.94B and has a P/E ratio of -17.86. Based on the recent corporate insider activity of 13 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SAIL in relation to earlier this year.
Yahoo
24 minutes ago
- Yahoo
News Media Group Partners with Tech Expert Marc Saltzman to Unlock the 'Smart' in Home Living
Nationwide Satellite Media Tour (SMT) Highlights Innovative Smart Home Solutions for Everyday Home Frustrations West Palm Beach, Florida--(Newsfile Corp. - June 11, 2025) - News Media Group, Inc., in collaboration with top technology brands and renowned Tech Expert Marc Saltzman recently showcased technology that helps transform the "Home Sweet Home" into a "Home Smart Home." Saltzman lead the nationwide SMT by featuring innovative products and services from top brands designed to help banish common household frustrations, including Wi-Fi dead zones outside the home, bringing reliable and affordable internet into the home, securing Amazon deliveries from theft and bad weather, avoiding unexpected water leaks, and an easier way to manage smart home. This compelling tour demonstrated how cutting edge technology can offer easy practical fixes that make daily home life smoother, safer, and better for consumers nationwide. A recap of the roundup of products along with details can be found on Cannot view this video? Visit: Brands that were featured in the SMT included: The eero Outdoor 7 expands eero Wi-Fi network inside homes to outside homes with weatherproof Wi-Fi 7 technology. T-Mobile 5G Home Internet provides Internet with unlimited data, 15-minute self-installation, no annual contracts and no equipment fees. Amazon Key In-Garage Delivery is a way to have Amazon packages, Amazon Fresh orders, and Whole Foods Market orders delivered inside garages. The Moen Flo Smart Water Monitor and Shutoff is a smart water device that monitors for leaks and takes action to help prevent them. Vivint, an NRG company, is a U.S. smart home company redefining the home experience through intelligent products and services. All the details and links can be found on Media Contact Details:Karl WayneExecutive Producer/PartnerNews Media Group, To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
